With a recent investment in the laboratory instruments and an expansion of the labs' capabilities, SGS will now be able to provide clients with toxicological profiles of biopharmaceuticals and medical devices.
The investment allows for an expansion of cell and tissue culture capabilities, flow cytometry, and mass spectrometry facilities. It also provides new high throughput screening, automation, and multiplexing technologies, including the Meso Sector S 600 for biomarker analysis.
This new suite covers more than 50 analytical techniques, including dermal and ocular toxicity, cytotoxicity, genotoxicitiy, carcinogenicity, phototoxicity, endocrine disruption, hepatotoxicity, and cardiotoxicity.
Alex Perieteanu, director of biopharmaceutical services at SGS Canada said in a press release that this investment matches up with “the three Rs – the principles of replacement, reduction, and refinement.”
Perieteanu said that following these R’s leads to more humane experimental research and ensures patient safety while accelerating product development.
All services available will be under good laboratory practice (OECD, FDA Part 58) conditions.
The Mississauga facility has more than 200 staff that provide contract testing services within the biopharmaceutical, pharmaceutical, bioanalytical, and medical device segments.
SGS has 18 laboratories all of which offer contract analytical and bioanalytical services. In addition to testing services for the biopharmaceutical market, SGS also provides Phase I-IV clinical trial management, and data management and statistics services. The company also provides pharmacokinetic/pharmacodynamics (PK/PD) modeling and simulation, pharmacovigilance and regulatory consultancy.
